GlassScriptPhysician profile
Amalfi Blanco
NPI 1710171095
$1,985.53
in general payments reported to CMS, 2019-2025
9 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2024: $153 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $1,006.72 | 2025 | M22 |
| Coopervision INC. | $225.40 | 2024-2025 | Ortho-K Contact Lens, Onefit Contact Lens, Misight Contact Lens |
| Glaukos Corporation | $203.45 | 2025 | Photrexa Viscous and Photrexa |
| Dompe US, INC. | $149.50 | 2025 | Oxervate |
| Alcon Vision LLC | $135.41 | 2019 | |
| Aerie Pharmaceuticals, INC. | $112.92 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $108.04 | 2025 | Acuvue |
| Rxsight INC | $44.09 | 2025 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amalfi Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.